ADPT
Adaptive Biotechnologies Corporation
Stock
$28.35+0.98 (+3.58%)Close Oct 2, 2026
Cash flow statement
| Line | Last 12 months | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | −$21M | −$46M | −$95M | −$156M | −$184M | −$193M | −$150M | $205M | −$32M | −$35M |
| Capital expenditures | $3.0M | $3.0M | $3.7M | $11M | $16M | $62M | $19M | $11M | $6.3M | $2.4M |
| Free cash flow | −$24M | −$49M | −$99M | −$167M | −$200M | −$254M | −$168M | $194M | −$39M | −$37M |
| Stock-based compensation | $49M | $51M | $54M | $63M | $55M | $43M | $25M | $13M | $11M | $7.0M |
| Free cash flow margin | −7.8% | −17.7% | −55.3% | −98.1% | −108.1% | −164.9% | −171.3% | 228.3% | −69.3% | −97.0% |